Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Plans New Approval Pathways To Foster Earlier Access To Novel Drugs

Executive Summary

The Australian government has come up with a set of proposals for reforming the drug and medical device regulatory framework, which include speeding up access to innovative drugs through expedited and provisional approval mechanisms and greater use of assessments by overseas regulators. The changes will be phased in over a period of about three years and may include some recovery of costs from industry.

You may also be interested in...



Australia Launches Review Into Medicines Access & Affordability

Time has taken its toll on Australia’s National Medicines Policy since it was implemented in 2000.

Australia To Make Access To Unauthorized Products Faster And Less Bothersome

New proposals by Australia’s Therapeutic Goods Administration include developing a list of unauthorized drugs that could be made available to patients faster and more easily. A decision to include a product on the list would not be appealable, the TGA says.

No Delays Expected As Australian Bill On Faster Drug Approvals Goes To Parliament

The Australian parliament has held its first reading of a bill that will implement a number of new measures in the pharmaceutical area, including two new expedited drug approval pathways and a risk-based approach to variations.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel